SCHEMBL27201620

SCHEMBL27201620

O=C(O)N1CCCC(F)(c2ccccc2Br)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD11B1 P28845 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP3A4 P08684 4/20 0.36
HIF1A Q16665 2/20 0.36
PDK2 Q15119 1/20 0.36
GRM5 P41594 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HRH1 P35367 1/20 0.35
CYP1A2 P05177 3/20 0.34
PROKR1 Q8TCW9 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 2/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
TSHR P16473 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23357805 0.85 GAA (0.38) MEN1KMT2ASMN1; SMN2PDK2HTR2A
SCHEMBL27201548 0.82 MEN1 (0.39) MEN1KMT2AHSD11B1SMN1; SMN2CYP3A4
SCHEMBL27201562 0.81 USP30 (0.45) MEN1KMT2APDK2
SCHEMBL20141372 0.72 OPRL1 (0.42) HSD11B1ALDH1A1LMNA
SCHEMBL23357843 0.71 GAA (0.39) SMN1; SMN2PDK2ALDH1A1LMNA
SCHEMBL23291785 0.69 RORC (0.44) PDK2
SCHEMBL30334978 0.69 RORC (0.44) PDK2
SCHEMBL1660328 0.68 CA12 (0.45)
SCHEMBL21145398 0.67 USP30 (0.43) SMN1; SMN2HPGDALDH1A1LMNANPC1
SCHEMBL21145396 0.67 USP30 (0.43) SMN1; SMN2HPGDALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP MEN1 2285/4885KMT2A 1959/4885HSD11B1 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.